The European Commission (EC) has already approved Valneva’s chikungunya vaccine Ixchiq for use in individuals aged 18 years ...

The US company’s rabies candidate, RBI-4000, was able to elicit an immune response comparable to Bavarian Nordic’s RavAvert.

Financial guidance for 2025 in line with the Company's 2024-2027 ambitions. COPENHAGEN, Denmark, February 3, 2025 - Bavarian Nordic A/S (OMX: BAVA) today announced preliminary, unaudited financial ...

Valneva’s chikungunya vaccine Ixchiq has been greenlit by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) ...

COPENHAGEN - Bavarian Nordic A/S (OMX:CSE:BAVA) shares fell 10% after the Danish vaccine maker reported preliminary 2024 results and provided 2025 guidance that failed to impress investors. The ...

The EMA's human medicines committee has recommended approval for Bavarian Nordic's chikungunya vaccine, which is shaping up to be the first alternative to a rival shot from Valneva. The CHIKV VLP ...

GN Store Nord A/S was the biggest leader among large stocks during the session, rising 8.4%, and BioGaia AB Series B rose 6.2%. Hemnet Group AB rounded out the top three leaders on Tuesday, with ...

Bavarian Nordic's own pipeline is led by its universal COVID-19 booster candidate, which is due to start phase 3 later this year, and respiratory syncytial virus (RSV) candidate that should ...

In Europe, the Stoxx Europe 600 fell 0.2% in morning trading. Infineon Technologies rose 10.4% and Coloplast Series B added 2.8%. On the other hand, Bavarian Nordic slipped 9.3%, and Vodafone Group ...

European stocks were unimpressed with the 30-day pause on US President Donald Trump’s planned tariffs on Canada and Mexico and started Tuesday’s session in negative territory after China unveiled ...

Hundreds of thousands of doses of moxidectin – which treats a disease caused by a parasitic worm – are being given to ...